Table 1.
Treatment | Dead embryos | Surviving fingerlings | ||||
---|---|---|---|---|---|---|
Total analyzed | Mutated | Mean mutation % ± SEM | Total analyzed | Mutated | Mean mutation % ± SEM | |
TICAM 1* | ||||||
Low | 22 | 15 | 68.2 ± 5.51 | 50 | 30 | 60.0 ± 1.12 |
Medium | 19 | 16 | 84.2 ± 11.81 | 13 | 9 | 69.2 ± 28.57 |
High | 25 | 22 | 88.0 ± 7.39 | 16 | 12 | 75.0 ± 13.33 |
RBL** | ||||||
Low | 26 | 23 | 88.5 ± 7.22 | 33 | 26 | 78.8 ± 4.84 |
Medium | 26 | 24 | 92.3 ± 5.82 | 12 | 10 | 83.3 ± 2.86 |
High | 28 | 26 | 92.9 ± 4.17 | 14 | 13 | 92.9 ± 4.17 |
TICAM 1 and RBL combined*** | ||||||
Low | 48 | 38 | 79.2 ± 5.35 | 83 | 56 | 67.5 ± 4.96 |
Medium | 45 | 40 | 88.9 ± 6.17 | 25 | 19 | 76.0 ± 12.18 |
High | 53 | 48 | 90.6 ± 4.08 | 30 | 25 | 83.3 ± 7.76 |
The three gRNA/Cas9 protein dosages were: low dosage: 2.5 ng gRNA/7.5 ng Cas9, medium dosage: 5 ng gRNA/15 ng Cas9 and high dosage: 7.5 ng gRNA/22.5 ng Cas9.
*Positive correlation between gRNA/Cas9 dosage and mutation rate (p = 0.084).
**Positive correlation between gRNA/Cas9 dosage and mutation rate (p = 0.025).
***Positive correlation between gRNA/Cas9 dosage and mutation rate (p = 0.013).